H
HaploX Biotechnology
Shenzhen-based genetic sequencing company
About HaploX Biotechnology
Founded in 2014 by Mingyan Xu, Wen Yuan, Fang Wen, and Chen Shi Fu, HaploX Biotechnology is a Shenzhen-based enterprise focused on genomic and precision medicine. Mingyan Xu, who serves as the Chairman and CEO, leads the company. The company has established itself in the field of ultra-micro tumor gene detection, leveraging genomics technology for cancer diagnosis. HaploX has secured significant funding across multiple rounds, including a Series A in 2016, a $32 million Series A+ in 2018, and subsequent Series B, C, and D rounds, with its latest funding round being a Series D in July 2022.
HaploX operates in the biotechnology and diagnostic equipment industries, specializing in liquid biopsy, gene sequencing, bioinformatics, and big data analytics. The company's business model centers on providing comprehensive genetic testing solutions and services. Its clients include Class IIIA hospitals, biopharmaceutical companies, research institutes, health examination centers, insurance companies, and government bodies across China. Revenue is generated through these services, which cover the full cycle of cancer management, from early screening and diagnosis to health management and risk assessment. The company has also formed a strategic partnership with Illumina, a global leader in DNA sequencing, to domestically produce a genetic sequencing system, signaling a strategic shift from a service provider to a developer of clinical application products.
The company's core offering involves advanced technology for capturing circulating tumor DNA (ctDNA) and extracting and amplifying minute amounts of DNA from liquid samples. Its product and service portfolio is extensive, including pan-solid tumor gene testing, minimal residual disease (MRD) gene testing, and hereditary cancer gene testing under brand names like HapOnco®. Additionally, HaploX provides multi-omics technology services for research, covering human, plant, animal, and microbial genomics, transcriptomics, and single-cell sequencing. For the biopharmaceutical sector, it offers central laboratory services, patient recruitment, and exploratory research services. The company's laboratories have received accreditations from the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA).
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Jul 2022 | $28M | $110M | SB China Capital · Tongrentang Pension Investment · CNCB Capital · Tongrentang | ↗ |
| SERIES BOther financing | Jun 2018 | $30M | $121M | Shenzhen Capital Group | — |
Growth signals
Latest recorded traffic for HaploX Biotechnology is 1.3K monthly website visits, down 7.1% over the last three months. HaploX Biotechnology's team declined 4.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
HaploX Biotechnology in the Shenzhen ecosystem
The HaploX Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later4 investors entered at this stage
SB China Capital- TITongrentang Pension Investment
CNCB Capital- TOTongrentang
Other known investors1 additional known investor
University of New Mexico
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about HaploX Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See HaploX Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










